4Saltzman AJ,Mehran R, Hooper WC,et al. The relative effects of ab-ciximab and tirofiban on platelet inhibition and C -reactive proteinduring coronary intervention [J]. J Invasive Cardiol, 2010,22 : 2-6.
5Thiele H,Schindler K,Friedenberger J,et al. Intracoronary comparedwith intravenous bolus abciximab application in patients with ST-el-evation myocardial infarction undergoing primary percutaneous coro-nary intervention : the randomized Leipzig immediate percutaneouscoronary Intervention abciximab IV versus IC in ST -elevation my-ocardial infarction trial [J]. Circulation, 2008,18: 49-57.
6Bovill EG,Terrin Ml,Stump Dc,et al. Hemorrhagic events duringtherpy with recomibinant tissue -ype plasminogen activator heparinand aspirin for acute myocardial infarction. Result of the thrombojysisin myocardial infarction (TIMI)Phase II trial [J]. Ann Inter Med,1991,1154.-256-265.
7Napodano M,Ramondo A,Tarantini G. Predictors and time -relatedimpact of distal embolization during primary angioplasty [J]. EurHeart J,2009,30:305-313.
8Fokkema ML, Vleuten PA. Incidence, predictors, and outcome of rein-farction and stent thrombosis within one year after primary percuta-neous coronary intervention for ST-elevation mvocaTdiai infarction [J].Catheter Cardiovasc Interv,2009,73:627-634.
9Okamura A,Ito H, Iwakura K,et al. Clinical implications of distalembolization during coronary interventional procedures in patientswith acute myocardial infarction : quantitative study with Dopplerguidewire [J]. JACC Cardiovasc Inter V, 2008,1 : 268-276.
10De Luca G,Ucci G,Cassetti E,et al. Benefits from small moleculeadministration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angio-plasty : a meta-analysis [J]. J Am Coll Cardiol ,2009,53 : 1668-1673.
